Upstream Bio, Inc. (NASDAQ:UPB) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $45.25.

UPB has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, October 8th. Mizuho started coverage on shares of Upstream Bio in a research note on Wednesday. They issued an “outperform” rating and a $51.00 price objective for the company. Lifesci Capital started coverage on shares of Upstream Bio in a report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 target price on the stock. Truist Financial assumed coverage on shares of Upstream Bio in a research report on Tuesday, October 14th. They issued a “buy” rating and a $47.00 price objective on the stock. Finally, Evercore ISI assumed coverage on Upstream Bio in a research note on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target for the company.

Upstream Bio Stock Up 4.6%

Shares of NASDAQ:UPB traded up $1.30 during trading on Thursday, hitting $29.63. 23,401 shares of the company were exchanged, compared to its average volume of 395,244. The company has a market capitalization of $1.60 billion, a P/E ratio of -15.72 and a beta of 1.83. The business’s 50 day moving average is $24.93 and its 200-day moving average is $18.27. Upstream Bio has a 1-year low of $5.14 and a 1-year high of $33.00.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.15. Upstream Bio had a negative return on equity of 28.71% and a negative net margin of 4,366.77%.The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.65 million. As a group, sell-side analysts anticipate that Upstream Bio will post -4.3 earnings per share for the current year.

Institutional Investors Weigh In On Upstream Bio

A number of large investors have recently modified their holdings of the stock. Nuveen LLC bought a new stake in Upstream Bio during the first quarter valued at about $138,000. Bain Capital Life Sciences Investors LLC boosted its stake in shares of Upstream Bio by 6.3% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock worth $26,786,000 after purchasing an additional 144,216 shares during the period. Parkman Healthcare Partners LLC bought a new stake in shares of Upstream Bio during the 1st quarter worth approximately $1,429,000. Geode Capital Management LLC increased its stake in Upstream Bio by 57.5% in the 2nd quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock worth $7,101,000 after buying an additional 235,958 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in Upstream Bio during the 1st quarter worth $92,000.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.